Lifecore Biomedical, Inc. (LFCR) is a fully integrated contract development and manufacturing organization (CDMO) specializing in the development, fill, and finish of complex sterile injectable pharmaceutical products. The company manufactures premium, injectable-grade sodium hyaluronate (HA) used as an active pharmaceutical ingredient (API) in various medical applications. Lifecore operates across multiple facilities, providing pharmaceutical-grade products and services to global biopharmaceutical and biotechnology companies.
- Contract Development and Manufacturing Organization (CDMO) - Develops, fills, and finishes sterile injectable pharmaceutical products in syringes, vials, and cartridges, offering services such as formulation technology development, analytical method development, clinical production, and commercial production.
- Sodium Hyaluronate (HA) Manufacturing - Produces premium, injectable-grade HA using fermentation processes, supporting applications in wound care, aesthetic surgery, drug delivery, orthopedics, and device coatings.
You might also like
- How do you expect potential shifts toward domestic drug manufacturing, as discussed at DCAT, to impact your cost structure and competitive positioning, especially given the current operational margins?
- With the Humanetics tech transfer contract being characterized as a Phase II project, can you clarify the specific regulatory and operational challenges you anticipate in transitioning this program?
- Considering your goal of a 12% revenue CAGR and over 25% EBITDA margins amid ongoing legacy legal expenses and adjustments in SG&A, what measures are in place to ensure these targets remain achievable?
- Given the noted decline in CDMO revenues and gross profit, what specific strategies will you employ to reverse this trend while capitalizing on the growth in HA manufacturing?
- In light of your Q3 cash flow being close to free cash flow breakeven, what contingency plans do you have if the remaining $10 million from the filler sale is delayed or if CapEx exceeds your guidance?
Research analysts who have asked questions during LIFECORE BIOMEDICAL, INC. \DE\ earnings calls.
Matthew Hewitt
Craig-Hallum Capital Group LLC
4 questions for LFCR
Also covers: ACET, APYX, BHST +21 more
Michael Petusky
Barrington Research
4 questions for LFCR
Also covers: ANIK, HAE, HSIC +8 more
Jacob Johnson
Stephens Inc.
1 question for LFCR
Also covers: AZTA, CDMO, CDXS +11 more
Max Smock
William Blair & Company
1 question for LFCR
Also covers: CDMO, CERT, CRL +7 more
Steven Etoch
Stephens Inc.
1 question for LFCR
Also covers: STE, STVN
| Customer | Relationship | Segment | Details |
|---|---|---|---|
Alcon | Major customer and lender | All | 44% of total revenue in FY 2025, or approximately $56.70 million (44% of $128.867 million). $173.5 million outstanding under the Term Loan. |
Recent press releases and 8-K filings for LFCR.
Lifecore Biomedical, Inc. Furnishes Investor Presentation Outlining Growth Strategy and Financial Outlook
·$LFCRGuidance Update
New Projects/Investments
Revenue Acceleration/Inflection
- LIFECORE BIOMEDICAL, INC. (LFCR) filed an 8-K on August 12, 2025, to furnish an investor presentation outlining its strategic growth initiatives.
- For fiscal year 2025, the company reported $128.9 million in revenues. For the seven-month transition period from May 26 to December 31, 2025, LFCR projects revenues of $74 million to $76 million and Adjusted EBITDA of $12 million to $14 million.
- LFCR aims for an aggressive growth strategy, targeting a 12%+ Revenue CAGR and Adjusted EBITDA margins of 25%+ in the mid-term, supported by expanded capacity with a potential of ~$300 million annually.
- The company is also changing its fiscal year end to align with the calendar year, effective for the December 31, 2025 period.
Aug 12, 2025, 12:00 AM
Lifecore Biomedical Reports Q4 and FY 2025 Results, Announces Fiscal Year Change
·$LFCREarnings
Guidance Update
New Projects/Investments
- Lifecore Biomedical reported Fiscal Year 2025 revenue of $128.9 million, meeting full-year guidance, but recorded a net loss of $38.7 million.
- For the fourth quarter of Fiscal 2025, revenues were $36.4 million, a 4% decrease compared to the prior year, with a net loss of $1.1 million.
- The company signed nine new programs with new customers during Fiscal 2025, reflecting growth into modalities beyond ophthalmic therapeutics, and secured additional new customer agreements subsequent to quarter end.
- Lifecore is moving its fiscal year end to align with the calendar year, effective for the December 31, 2025 period. For the approximately seven-month transition period (May 26 to December 31, 2025), the company expects revenue of $74 to $76 million and Adjusted EBITDA of $12 to $14 million.
Aug 7, 2025, 12:00 AM
LifeCore Biomedical Approves Convertible Preferred Issuance Proposal
·$LFCRProxy Vote Outcomes
Convertible Preferred Issuance
- On April 10, 2025, LifeCore Biomedical held a special stockholders meeting (with a record date of February 18, 2025) to address a proposal concerning the issuance of shares underlying Series A Convertible Preferred Stock, along with an adjournment proposal.
- The meeting resulted in the approval of the issuance proposal, with 24,098,218 votes for, 444,639 votes against, and 33,281 abstentions; the adjunct adjournment proposal was approved in principle but not executed due to the issuance proposal's success.
Apr 10, 2025, 12:00 AM